Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1

Annals of the Rheumatic Diseases

Volumn 71, Issue 12, 2012, Pages 2051-2054

  Palumbo Zerr, Katrin ^a   Horn, Angelika ^a   Distler, Alfiya ^a   Zerr, Pawel ^a   Dees, Clara ^a   Beyer, Christian ^a   Selvi, Enrico ^b   Cravatt, Benjamin F ^c   Distler, Oliver ^d   Schett, Georg ^a   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF SIENA   (Italy)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; HYDROXYPROLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME INACTIVATION; FIBROBLAST; FIBROSIS; GENE INACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS;

AMIDOHYDROLASES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; ENDOCANNABINOIDS; FEMALE; FIBROBLASTS; FIBROSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SKIN DISEASES;

EID: 84868480319     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201823     Document Type: Article

References (20)

1. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 2008;20(Suppl 1):10-14.
2. Bisogno T. Endogenous cannabinoids: structure and metabolism. J Neuroendocrinol 2008;20(Suppl 1):1-9.
3. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.
4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5.
5. Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001;98:9371-6.
6. Akhmetshina A, Dees C, Busch N, et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 2009;60:1129-36.
7. Marquart S, Zerr P, Akhmetshina A, et al. Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum 2010;62:3467-76.
8. Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006;12:671-6.
9. Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
10. Mukhopadhyay P, Batkai S, Rajesh M, et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 2007;50:528-36.
11. Akhmetshina A, Dees C, Pileckyte M, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008;22:2214-22.
12. Beyer C, Reich N, Schindler SC, et al. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 2012;71:1019-26.
13. Dees C, Akhmetshina A, Zerr P, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011;208:961-72.
14. Bergmann C, Akhmetshina A, Dees C, et al. Inhibition of glycogen synthase kinase 3beta induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis 2011;70:2191-8.
15. Palumbo K, Zerr P, Tomcik M, et al. The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011;70:1320-6.
16. Hezode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005;42:63-71.
17. Garcia-Gonzalez E, Selvi E, Balistreri E, et al. Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology (Oxford) 2009;48:1050-6.
18. Gonzalez EG, Selvi E, Balistreri E, et al. Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Ann Rheum Dis 2012;711:545-51.
19. Selvi E, Lorenzini S, Garcia-Gonzalez E, et al. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin Exp Rheumatol 2008;26:574-81.
20. Klein TW, Newton C, Larsen K, et al. Cannabinoid receptors and T helper cells. J Neuroimmunol 2004;147:91-4.